ReviewSeminars in immunopathology2019
Resolution of ulcerative colitis.
Review in Seminars in immunopathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Efficacy and safety of gut microbiota-based therapies in autoimmune and rheumatic diseases: a systematic review and meta-analysis of 80 randomized controlled trials.BMC medicine · 2024Pooled it
- Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis.The Cochrane database of systematic reviews · 2022Pooled it
- Loganin alleviates oxidative stress-induced apoptosis by modulating mitochondrial function and STAT3 signaling in DSS-induced colitis and HScientific reports · 2026Article
- Integrated multi-omics profiling of gut microbiome and metabolome in ulcerative colitis insights from the Iranian population.iScience · 2026Article
- Exploring the Treatment of Cinnamomum Cassia Leaf Extract in Ulcerative Colitis: Network Pharmacology and In Vitro Investigations.Plants (Basel, Switzerland) · 2026Article
- Therapeutic impacts of oral anti-diabetic drugs on Inflammatory Bowel Disease (IBD), a comprehensive review of clinical and preclinical studies.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Gegen Qinlian decoction alleviates DSS-induced colitis in mice through coordinated modulation of gut microbiota, serum metabolome, and colonic γδT cell responses.Frontiers in immunology · 2026Article
- Emulating Hyperspectral and Narrow-Band Imaging for Deep-Learning-Driven Gastrointestinal Disorder Detection in Wireless Capsule Endoscopy.Bioengineering (Basel, Switzerland) · 2025Article
- Hydrogel derived from decellularized pig small intestine submucosa boosted the therapeutic effect of FGF-20 on TNBS-induced colitis in rats via restoring gut mucosal integrity.Materials today. Bio · 2025Article
- Improvement of the inflammation-damaged intestinal barrier and modulation of the gut microbiota in ulcerative colitis after FMT in the SHIME® model.BMC complementary medicine and therapies · 2025Article
- Molecular insights into ulcerative colitis and orbital inflammation.Scientific reports · 2025Article
- Identification of shared and unique mechanisms of atopic dermatitis and ulcerative colitis by construction and computational analysis of disease maps.Computational and structural biotechnology journal · 2025Article
- Advances in gut microbiota functions in inflammatory bowel disease: Dysbiosis, management, cytotoxicity assessment, and therapeutic perspectives.Computational and structural biotechnology journal · 2025Review
- Mucosal Bacterial Immunotherapy Attenuates the Development of Experimental Colitis by Reducing Inflammation Through the Regulation of Myeloid Cells.International journal of molecular sciences · 2024Article
- Article
- Methionine-choline deficient diet deteriorates DSS-induced murine colitis through disturbance of gut microbes and infiltration of macrophages.Acta pharmacologica Sinica · 2024Article
- Review
- Does type 1 diabetes serve as a protective factor against inflammatory bowel disease: A Mendelian randomization study.World journal of diabetes · 2024Article
- Blockade of PI3K/AKT signaling pathway by Astragaloside IV attenuates ulcerative colitis via improving the intestinal epithelial barrier.Journal of translational medicine · 2024Article
- Paeoniflorin improves ulcerative colitis via regulation of PI3K‑AKT based on network pharmacology analysis.Experimental and therapeutic medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis designates an idiopathic chronic inflammatory bowel disease leading to bloody diarrhea and inflammatory alterations mostly restricted to the large intestine. Many studies continue to unravel important aspects of its etiopathogenesis, and recent pharmaceutical developments broaden the arsenal of therapeutic opportunity. In this review, we delve into the cellular and molecular determinants of successful resolution of ulcerative colitis, describing novel insights in each of the phases of mucosal healing starting from damaging insults to the mucosa, epithelial restitution, and its adaption to inflammation as well as lymphocyte-driven maintenance and resolution of chronic inflammation. Additionally, molecular switches from inflammation to resolution are explored, paving the way for future avenues to resolve ulcerative colitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.